On March 9, the Student Global AIDS Campaign demanded that Abbott Laboratories Chairman of the Board and CEO Miles White make Kaletra, a critical HIV treatment, more accessible and affordable. Members of the nation's largest student AIDS advocacy organization called, faxed and mailed letters to White in an effort to persuade him.
Kaletra inhibits the replication of HIV, which has become resistant to many previously effective drugs. According to a campaign press release, the new version of the drug requires no refrigeration; therefore, it is ideal for use in regions without electricity.
Students insist that Abbott, among other things, make Kaletra available to more countries and to increase research and development of new Kaletra pediatric concoctions.
